The decision comes as at least 10 states are opening up booster dose eligibility beyond the current, more limited authorizations while cases remain at high levels.
Lawmakers on Tuesday introduced a revised MCIT proposal in the next version of the 21st Century Cures Act, following last week’s repeal of the final rule by CMS. Industry groups AdvaMed and MDMA both back the legislation.
Payers and employers will need to give HHS an annual overview of the top 50 drugs across different areas, including the most frequently dispensed drugs and the most expensive prescription drugs.
Healthcare workers in children’s hospitals had the highest vaccination rates, along with those working in metropolitan counties, according to the analysis of Centers for Disease Control and Prevention data.
Despite strong year-over-year revenue growth, the finances of Bright, Clover and Oscar were whalloped by coronavirus and risk adjustment headwinds.
The nonprofit is currently in discussions with an undisclosed third party to negotiate the divestiture of its North Dakota and Minnesota facilities, according to its first quarter results.
While payers and providers must start complying with the No Surprises Act by Jan. 1, the fight over rules implementing the ban is heating up as provider groups object to what they think is a favoring of insurers.
The agency’s final guidance on the practice of sharing resources in an effort to improve provider efficiency drew praise from the American Hospital Association.
Study results released earlier this month showed the pill, when given soon after symptoms start, dramatically reduced the risk of COVID-19 hospitalization or death.
In a new report, ICER highlighted AbbVie’s price hikes on Humira, which the group said resulted in more than $1 billion in U.S. spending last year without any new evidence of health benefits.